<DOC>
	<DOC>NCT02229877</DOC>
	<brief_summary>The purpose of this study is to: determine the effect of stomach pH on the multiple dose pharmacokinetics (PK) of AF-219; assess the effect of multiple doses of AF-219 on various sensory assessments; and, assess the safety and tolerability of AF-219.</brief_summary>
	<brief_title>A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of AF-219</brief_title>
	<detailed_description />
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Must be informed of the nature of the study and have provided written informed voluntary consent; Able to speak, read, and understand English; Healthy males or females, of any race, between 18 and 55 years of age, inclusive; Body mass index (BMI) &gt;18.5 and &lt;32.0 kg/m2 and weigh 50 100 kg; In good general health ; Nonsmokers for at least 5 years; If a female of childbearing potential (i.e., have not undergone a hysterectomy or bilateral oophorectomy) or not postmenopausal (defined as no menses for at least 12 months), agree to use 2 forms of acceptable birth control; or if a male, they and/or their partner of childbearing potential agree to use 2 forms of acceptable birth control; Any disease or condition that might affect drug absorption, metabolism, or excretion or clinically significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease; Clinically significant illness or clinically significant surgery within 4 weeks before the administration of study medication; Any past sinus surgery, upper respiratory tract infection within 2 weeks before dosing, or history of hay fever during the time of the year that dosing will be taking place; History of GERD, heartburn, or nausea more than once a month, or any similar symptoms requiring the regular use of antacids, or any use of H2 histamine blockers or proton pump inhibitors within 12 months of Screening; Have a positive screening test for Helicobacter pylori; QTcB &gt;450 msec in males or &gt;460 msec in females; Known or suspected hypersensitivity or allergic reaction to any of the components of AF219 or omeprazole capsules; If female, is pregnant or breast feeding, or has a positive pregnancy test pre dose; Blood loss or blood donation of &gt;550 mL within 90 days or plasma donation &gt;500 mL within 14 days before administration of the first dose of study drug; Chronic use of any systemic medications; use of a drug therapy known to induce or inhibit hepatic drug metabolism within 30 days before the first dose of study medication; or use of any medications including antacids, high dose multivitamins, nutritional supplements, and herbal preparations, within 14 days before the first dose of study drug; Past or current history or evidence of drug or alcohol abuse, use of any recreational soft drugs (e.g., marijuana) within 3 months of screening, use of any hard drugs (such as cocaine, phencyclidine (PCP), and crack) within 1 year of screening, and/or a positive screen for substances of abuse or alcohol at screening or pre dose; Ingestion of grapefruit or grapefruit juice within 48 hours before dose administration; Positive urine cotinine test at Screening or Day 1 pre dose; Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C antibody, or human immunodeficiency virus (HIV) antibody; Receipt of an investigational product or device, or participation in a drug research study within a period of 30 days (or 5 half lives of the drug, whichever is longer) before the first dose of study medication; Receipt of an investigational immunomodulator or monoclonal antibody within 180 days (or 5 half lives, whichever is longer) before the first dose of study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>